Reactions 1704, p337 - 2 Jun 2018
Recurrent hypertension: case report
In a retrospective study that included 41 patients, a patient
[age and sex not stated] was described, who developed
recurrent hypertension during treatment with rivoceranib
[apatinib] for metastatic colorectal cancer [duration of
treatment to reaction onset not stated].
The patient, who had metastatic colorectal cancer, received
treatment with oral rivoceranib 500mg once daily for 28 days.
Prior to the initiation of rivoceranib treatment, the patient had
received atleast two lines of chemotherapy [specific drug not
stated]. During the rivoceranib therapy, the patient developed
recurrent grade 3 hypertension.
As the patient’s recurrent hypertension was considered to
be related to the use of rivoceranib, the dose of rivoceranib
was reduced to 250mg once daily [outcome not stated].
Author comment: "All patients initially received a daily
oral dose of 500 mg of apatinib. However, the dose was
reduced to 250 mg in one patient due to recurrent grade 3
hypertension." "One dose reduction (to 250 mg) for drug-
related grade 3 or 4 toxicity was allowed."
Lv W, et al. Efficacy and safety of apatinib in patients with metastatic colorectal
cancer refractory to standard therapies. Translational Cancer Research 7: 420-427,
No. 2, Apr 2018. Available from: URL: http://doi.org/10.21037/tcr.2018.04.03 -
Reactions 2 Jun 2018 No. 17040114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved